JP2004523555A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004523555A5 JP2004523555A5 JP2002567292A JP2002567292A JP2004523555A5 JP 2004523555 A5 JP2004523555 A5 JP 2004523555A5 JP 2002567292 A JP2002567292 A JP 2002567292A JP 2002567292 A JP2002567292 A JP 2002567292A JP 2004523555 A5 JP2004523555 A5 JP 2004523555A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- formula
- disease
- group
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 35
- 208000015122 neurodegenerative disease Diseases 0.000 claims 18
- 208000014674 injury Diseases 0.000 claims 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 208000027418 Wounds and injury Diseases 0.000 claims 11
- 230000006378 damage Effects 0.000 claims 11
- 230000001684 chronic effect Effects 0.000 claims 10
- 230000001154 acute effect Effects 0.000 claims 8
- 206010012289 Dementia Diseases 0.000 claims 6
- 206010008118 cerebral infarction Diseases 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 6
- 239000000460 chlorine Substances 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 208000029028 brain injury Diseases 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 206010021143 Hypoxia Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- 230000003902 lesion Effects 0.000 claims 4
- 201000001119 neuropathy Diseases 0.000 claims 4
- 230000007823 neuropathy Effects 0.000 claims 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 3
- 201000006474 Brain Ischemia Diseases 0.000 claims 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 3
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- 208000034656 Contusions Diseases 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 208000034693 Laceration Diseases 0.000 claims 3
- 230000009692 acute damage Effects 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 230000006835 compression Effects 0.000 claims 3
- 238000007906 compression Methods 0.000 claims 3
- 230000009519 contusion Effects 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 230000007850 degeneration Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 230000002124 endocrine Effects 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 230000001146 hypoxic effect Effects 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 239000011630 iodine Substances 0.000 claims 3
- 230000001537 neural effect Effects 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000000044 Amnesia Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 claims 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 208000005264 motor neuron disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 230000016273 neuron death Effects 0.000 claims 2
- 208000021090 palsy Diseases 0.000 claims 2
- 230000035515 penetration Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- 208000032527 type III spinal muscular atrophy Diseases 0.000 claims 2
- 206010002660 Anoxia Diseases 0.000 claims 1
- 241000976983 Anoxia Species 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims 1
- 102000007371 Ataxin-3 Human genes 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims 1
- 206010050389 Cerebral ataxia Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
- 206010057645 Chronic Inflammatory Demyelinating Polyradiculoneuropathy Diseases 0.000 claims 1
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims 1
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 208000001730 Familial dysautonomia Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000010496 Heart Arrest Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008574 Intracranial Hemorrhages Diseases 0.000 claims 1
- 208000027747 Kennedy disease Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 240000007817 Olea europaea Species 0.000 claims 1
- 206010033885 Paraparesis Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000019155 Radiation injury Diseases 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 201000001638 Riley-Day syndrome Diseases 0.000 claims 1
- 208000021811 Sandhoff disease Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims 1
- 208000032859 Synucleinopathies Diseases 0.000 claims 1
- 208000022292 Tay-Sachs disease Diseases 0.000 claims 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 1
- 206010063661 Vascular encephalopathy Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000030597 adult Refsum disease Diseases 0.000 claims 1
- 230000007953 anoxia Effects 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 208000025434 cerebellar degeneration Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000002920 convulsive effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 210000003792 cranial nerve Anatomy 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000003073 embolic effect Effects 0.000 claims 1
- 230000008175 fetal development Effects 0.000 claims 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 238000007917 intracranial administration Methods 0.000 claims 1
- 208000037906 ischaemic injury Diseases 0.000 claims 1
- 206010023497 kuru Diseases 0.000 claims 1
- 208000037805 labour Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 238000011458 pharmacological treatment Methods 0.000 claims 1
- 208000001282 primary progressive aphasia Diseases 0.000 claims 1
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 claims 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27168201P | 2001-02-27 | 2001-02-27 | |
| PCT/US2002/005541 WO2002067925A1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| US10/081,764 US20020165273A1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004523555A JP2004523555A (ja) | 2004-08-05 |
| JP2004523555A5 true JP2004523555A5 (enExample) | 2005-12-22 |
| JP4276840B2 JP4276840B2 (ja) | 2009-06-10 |
Family
ID=26765943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002567292A Expired - Fee Related JP4276840B2 (ja) | 2001-02-27 | 2002-02-21 | 神経変性障害の予防もしくは治療における使用のためのカルバメート化合物 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20020165273A1 (enExample) |
| EP (1) | EP1383489B1 (enExample) |
| JP (1) | JP4276840B2 (enExample) |
| KR (1) | KR100910928B1 (enExample) |
| CN (1) | CN1235579C (enExample) |
| AR (1) | AR035756A1 (enExample) |
| AT (1) | ATE361745T1 (enExample) |
| BR (1) | BR0207645A (enExample) |
| CA (1) | CA2439295C (enExample) |
| CY (1) | CY1106753T1 (enExample) |
| CZ (1) | CZ301203B6 (enExample) |
| DE (1) | DE60220043T2 (enExample) |
| DK (1) | DK1383489T3 (enExample) |
| ES (1) | ES2284845T3 (enExample) |
| HU (1) | HUP0303264A3 (enExample) |
| IL (2) | IL157591A0 (enExample) |
| MX (1) | MXPA03007718A (enExample) |
| MY (1) | MY138156A (enExample) |
| NO (1) | NO20033798L (enExample) |
| NZ (1) | NZ527990A (enExample) |
| PL (1) | PL364680A1 (enExample) |
| PT (1) | PT1383489E (enExample) |
| RS (1) | RS51055B (enExample) |
| RU (1) | RU2300373C2 (enExample) |
| TW (1) | TWI312679B (enExample) |
| WO (1) | WO2002067925A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005033092A1 (en) * | 2003-09-19 | 2005-04-14 | Galileo Pharmaceuticals, Inc. | Chroman derivatives |
| PT1809273E (pt) * | 2004-09-16 | 2010-05-10 | Janssen Pharmaceutica Nv | Utililização de 2-fenil-1,2-etanodiol-(di)carbamatos para tratamento de epileptogénese |
| BRPI0516112A (pt) * | 2004-10-15 | 2008-08-26 | Janssen Pharmaceutica Nv | métodos para neuroproteção |
| US20070021500A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods for neuroprotection |
| EP1928451B1 (en) * | 2005-07-26 | 2011-12-28 | SK Biopharmaceuticals Co., LTD | Methods for treating substance-related disorders |
| US7632963B2 (en) * | 2006-10-06 | 2009-12-15 | Janssen Pharmaceutica Nv | Crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate |
| CN101568362A (zh) * | 2006-10-30 | 2009-10-28 | 詹森药业有限公司 | 治疗抑郁症的方法 |
| JP2010508354A (ja) * | 2006-10-31 | 2010-03-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 広汎性発達障害の処置 |
| US9018253B2 (en) | 2010-07-02 | 2015-04-28 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| WO2012002773A2 (en) * | 2010-07-02 | 2012-01-05 | Bio-Pharm Solutions Co., Ltd. | Phenylcarbamate compound and muscle relaxant containing the same |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| WO2013036678A1 (en) * | 2011-09-07 | 2013-03-14 | Satori Pharmaceuticals, Inc. | Compounds useful for treating neurodegenerative disorders |
| RU2632659C2 (ru) | 2011-12-27 | 2017-10-09 | Байо-Фарм Солюшнс Ко., Лтд. | Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии |
| JP6062077B2 (ja) * | 2013-03-12 | 2017-01-18 | バイオ−ファーム ソリューションズ カンパニー リミテッド | 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｐｅｄｉａｔｒｉｃｅｐｉｌｅｓｙａｎｄｅｐｉｌｅｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅｓ｝ |
| WO2014142547A1 (en) * | 2013-03-12 | 2014-09-18 | Bio-Pharm Solutions Co., Ltd. | Phenyl carbamate compound and a composition for neuroprotection comprising the same |
| CN109071424B (zh) | 2016-02-29 | 2022-01-14 | 生物药品解决方案有限公司 | 氨基磺酸酯衍生物化合物、其制备方法及用途 |
| ES3035674T3 (en) | 2016-12-14 | 2025-09-08 | Sk Biopharmaceuticals Co Ltd | Use of carbamate compound for prevention, alleviation, or treatment of demyelinating disease |
| IL281559B2 (en) * | 2018-09-21 | 2025-06-01 | Sk Biopharmaceuticals Co Ltd | (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder |
| WO2022045824A1 (en) | 2020-08-31 | 2022-03-03 | Bio-Pharm Solutions Co., Ltd. | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease |
| US11896593B2 (en) | 2020-09-10 | 2024-02-13 | Bio-Pharm Solutions Co., Ltd. | Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
| US3278380A (en) * | 1962-02-06 | 1966-10-11 | Armour Pharma | Methods of calming employing diphenyl hydroxy carbamate compounds |
| US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
| US5474990A (en) * | 1989-10-20 | 1995-12-12 | Olney; John W. | Barbiturates as safening agents in conjunction with NMDA antagonists |
| CN1109880A (zh) * | 1994-02-03 | 1995-10-11 | 合成实验室公司 | 3-(2-氨基乙基)-4-[3-(三氟甲基)苯甲酰基]-3，4-二氢-2h-1，4-苯并噁嗪衍生物、制备及其应用 |
| US5492930A (en) * | 1994-04-25 | 1996-02-20 | Schering Corporation | Method and formulation for treating CNS disorders |
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US5728728A (en) * | 1996-04-10 | 1998-03-17 | Kozachuk; Walter E. | Methods of providing neuroprotection |
| US6232434B1 (en) * | 1996-08-02 | 2001-05-15 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| RS50676B (sr) * | 2001-02-27 | 2010-06-30 | Ortho-Mcneil Pharmaceutical Inc. | Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja |
| DK1401424T3 (da) * | 2001-02-27 | 2007-02-26 | Ortho Mcneil Pharm Inc | Carbamatforbindelser til anvendelse ved forebyggelse eller behandling af psykotiske forstyrrelser |
| HUP0303243A3 (en) * | 2001-02-27 | 2012-07-30 | Ortho Mcneil Pharm Inc | Carbamate compounds for use in preventing and treating bipolar disorder |
-
2002
- 2002-02-21 DE DE60220043T patent/DE60220043T2/de not_active Expired - Lifetime
- 2002-02-21 EP EP02714977A patent/EP1383489B1/en not_active Expired - Lifetime
- 2002-02-21 JP JP2002567292A patent/JP4276840B2/ja not_active Expired - Fee Related
- 2002-02-21 AT AT02714977T patent/ATE361745T1/de active
- 2002-02-21 CZ CZ20032313A patent/CZ301203B6/cs not_active IP Right Cessation
- 2002-02-21 BR BR0207645-4A patent/BR0207645A/pt not_active Application Discontinuation
- 2002-02-21 NZ NZ527990A patent/NZ527990A/en unknown
- 2002-02-21 PL PL02364680A patent/PL364680A1/xx unknown
- 2002-02-21 PT PT02714977T patent/PT1383489E/pt unknown
- 2002-02-21 HU HU0303264A patent/HUP0303264A3/hu unknown
- 2002-02-21 IL IL15759102A patent/IL157591A0/xx unknown
- 2002-02-21 RS YUP-674/03A patent/RS51055B/sr unknown
- 2002-02-21 KR KR1020037011302A patent/KR100910928B1/ko not_active Expired - Fee Related
- 2002-02-21 DK DK02714977T patent/DK1383489T3/da active
- 2002-02-21 ES ES02714977T patent/ES2284845T3/es not_active Expired - Lifetime
- 2002-02-21 RU RU2003128982/14A patent/RU2300373C2/ru not_active IP Right Cessation
- 2002-02-21 US US10/081,764 patent/US20020165273A1/en not_active Abandoned
- 2002-02-21 WO PCT/US2002/005541 patent/WO2002067925A1/en not_active Ceased
- 2002-02-21 CN CNB028087178A patent/CN1235579C/zh not_active Expired - Fee Related
- 2002-02-21 CA CA2439295A patent/CA2439295C/en not_active Expired - Fee Related
- 2002-02-21 MX MXPA03007718A patent/MXPA03007718A/es active IP Right Grant
- 2002-02-27 TW TW091103504A patent/TWI312679B/zh active
- 2002-02-27 MY MYPI20020697A patent/MY138156A/en unknown
- 2002-02-27 AR ARP020100697A patent/AR035756A1/es unknown
-
2003
- 2003-08-26 NO NO20033798A patent/NO20033798L/no not_active Application Discontinuation
- 2003-08-26 IL IL157591A patent/IL157591A/en not_active IP Right Cessation
-
2004
- 2004-03-10 US US10/797,795 patent/US20040171679A1/en not_active Abandoned
-
2007
- 2007-07-24 CY CY20071100982T patent/CY1106753T1/el unknown
-
2008
- 2008-09-10 US US12/207,816 patent/US20090005442A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005501801A5 (enExample) | ||
| RU2003128982A (ru) | Карбаматы для предотвращения или лечения нейродегенеративных нарушений | |
| KR101098490B1 (ko) | 3치환2（아릴알킬）1아자바이시클로알칸 및 그 사용방법 | |
| JP2021075556A5 (enExample) | ||
| DK1303495T3 (da) | Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet | |
| JP2008514627A5 (enExample) | ||
| TW200745135A (en) | Therapeutic agents | |
| CZ122598A3 (cs) | Použití 2-amino-4-/4-fluorbenzylamino/-ethoxykarbonylaminobenzenu pro profylaxi a léčení následků akutní a chronické mozkové nedokrevnosti jakož i neurodegenerativních onemocnění | |
| WO2012013728A1 (en) | Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use | |
| BR0011823A (pt) | Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo | |
| RU2003124059A (ru) | Лечение неврологической дисфункции с применением сульфаматов фруктопиранозы и эритропоэтина | |
| JP2009501224A5 (enExample) | ||
| EA016687B8 (ru) | Производные циклопропиламида | |
| JP2022539152A5 (enExample) | ||
| HRP20100304T1 (hr) | Uporaba 2-fenil-1,2-etanediol-(di)karbamata za liječenje epileptogeneze | |
| MA27591A1 (fr) | Agonistes du recepteur du facteur de liberation 2 de la corticotropine. | |
| Zeng et al. | Synthesis and evaluation of two 18F-labeled imidazo [1, 2-a] pyridine analogues as potential agents for imaging β-amyloid in Alzheimer’s disease | |
| TW200635589A (en) | Therapeutic agents | |
| JP2009501223A5 (enExample) | ||
| KR102467285B9 (ko) | 우황청심환을 포함하는 파킨슨 질환 예방 또는 치료용 약학 조성물 | |
| JP2019535715A5 (enExample) | ||
| Hausner et al. | Synthesis of 5-and 6-substituted 2-(4-dimethylaminophenyl)-1, 3-benzoxazoles and their in vitro and in vivo evaluation as imaging agents for amyloid plaque | |
| IL101560A0 (en) | Condensed diazepinones,their preparation and pharmaceutical compositions containing them | |
| Tian et al. | The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor type 1 | |
| EP2714651A1 (en) | N,n-substituted guanidine compound |